Clinical Trials Logo

Filter by:
NCT ID: NCT00652925 Completed - Clinical trials for Arthritis, Juvenile Rheumatoid

A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA

Start date: October 2002
Phase: Phase 3
Study type: Interventional

To study Celebrex versus naproxen to see if it decreases symptoms of juvenile arthritis such as pain and swelling.

NCT ID: NCT00652470 Completed - Hydrocephalus Clinical Trials

A Study Comparing Two Treatments for Infants With Hydrocephalus

Start date: September 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to study whether infants with triventricular hydrocephalus (TVH) have a better long-term outcome at 5 years when they are treated with a new procedure, endoscopic third ventriculostomy (ETV), than infants treated with the more traditional treatment, insertion of a cerebrospinal fluid (CSF) shunt.

NCT ID: NCT00652366 Completed - Pancreatic Cancer Clinical Trials

A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Start date: May 2008
Phase: Phase 2
Study type: Interventional

This study will compare the efficacy and safety of escalating versus standard doses to rash of Tarceva, in combination with gemcitabine, in patients with metastatic pancreatic cancer. During a 4 week run-in period, all patients will receive Tarceva 100mg/day po plus gemcitabine 1000mg/m2 iv on days 1, 8,15 and 22. After 4 weeks, patients who have not developed rash, or only develop grade 1 rash, will be randomized to one of 2 groups. Group 1 will receive a starting dose of Tarceva 150mg po daily, increased in steps of 50mg every 2 weeks up to a maximum of 250mg/day po, until development of grade 2 rash or other dose-limiting toxicity. Group 2 will continue to receive Tarceva 100mg/day po. All patients will continue to receive gemcitabine 1000mg/m2 iv on days 1, 8 and 15 of each 4 week cycle. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.

NCT ID: NCT00651248 Completed - Oral Health Clinical Trials

Evaluation of Salivary Flow and Buffer Capacity Associated to Aged People's Oral Health

Start date: September 2006
Phase: N/A
Study type: Observational

The purpose of this study is to identify the relation of the salivary flow and the buffer capacity of the saliva with medicine, buccal discomfort and auto-related illnesses in aged people.

NCT ID: NCT00651209 Completed - Clinical trials for Hepatitis B, Chronic

A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)

Start date: February 2008
Phase: Phase 4
Study type: Interventional

This study will evaluate the use of telbivudine for patients with HBeAg-positive CHB with an option to intensify treatment at Week 24 by adding tenofovir for patients who do not achieve HBV DNA non-detectability.

NCT ID: NCT00650767 Completed - Clinical trials for Rheumatoid Arthritis

A Study of ARRY-438162 in Patients With Rheumatoid Arthritis

Start date: March 2008
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study, involving a 12-week treatment period, designed to evaluate the effectiveness of investigational study drug ARRY-438162 in treating rheumatoid arthritis in patients on stable doses of methotrexate, and to further evaluate the safety of the study drug. Approximately 200 patients from the US, Argentina, Brazil, Hungary, Peru, Poland and Romania will be enrolled in this study.

NCT ID: NCT00649610 Completed - Low Back Pain Clinical Trials

Randomized, Double Blind, Multicenter Study of the Safety and Efficacy of Valdecoxib 40 mg Once Daily Compared With Diclofenac 75 mg Twice Daily in Acute Low Back Pain

Start date: November 2002
Phase: Phase 4
Study type: Interventional

The pain relief, safety, and tolerability of valdecoxib 40 mg once daily compared with diclofenac 75 mg twice daily for acute low back pain was studied. The effect of valdecoxib on the patient's level of disability and quality of life was also studied.

NCT ID: NCT00649415 Completed - Dysmenorrhea Clinical Trials

A Double Blind, Double Dummy, Randomized, Comparative Study Of The Efficacy And Safety Of Valdecoxib 40 Mg Twice Daily, As Needed In The First Menstrual Cycle Day And Then Once A Day, And Piroxicam 40 Mg Once A Day In The Treatment Of Patients With Primary Dysmenorrhea

Start date: January 2003
Phase: Phase 4
Study type: Interventional

To compare the analgesic efficacy, safety, and tolerability of valdecoxib versus piroxicam in subjects with moderate to severe menstrual cramping pain associated with primary dysmenorrhea.

NCT ID: NCT00648687 Completed - Clinical trials for Retinopathy of Prematurity

Pain Response During Examination for Retinopathy of Prematurity

ROP
Start date: March 2008
Phase: N/A
Study type: Interventional

Newborns infants equal or less than 1500 grams and/or equal and less than 32 weeks will have ophthalmologic examination for ROP at 6 weeks old. They will be randomized blindly to receive 2 ml of 12.5% dextrose in water (D12.5W) orally five minute before examination (intervention group) or nothing (control). NIPS scale will be applied two minutes before examination and two minutes after examination.

NCT ID: NCT00646737 Completed - Clinical trials for Kidney Transplantation

Conversion From Mycophenolate Mofetil to Mycophenolate Sodium in Renal Transplant

Start date: May 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the safety and the tolerability of the substitution of mycophenolate mofetil for enteric-coated mycophenolate sodium in a population of stable renal transplant patients in Brazil, in a treatment regimen of immunosuppressants with tacrolimus and mycophenolate mofetil.